A Closer Look at Spravato (Esketamine): How will it be administered?

As the P.R. machine kicks into gear to support the launch of Spravato/Esketamine, the first FDA approved Ketamine-derived treatment, Kevin Nicholson (President, CEO of Ketamine Wellness Centers) digs into the details that tend to receive less attention.

This episode focuses on how Spravato is administered:

Is intranasal delivery effective?

What type of clinical environments can provide Spravato to patients?

What duration of time will patients have to commit to treatment?

www.ketaminewellnesscenters.com/category/podcast/